Lumateperone (ITI-007) for Schizophrenia
Lumateperone for Schizophrenia
Sponsor: Intra-Cellular Therapies
Enrolling: Male and Female Patients
Study Length: 199 Days
Clinic Visits: 12
IRB Number: 7716
U.S. Govt. ID: NCT03817528
Contact: Marlene Carlson, MPH: 646-774-8436 / mc157@columbia.edu
Additional Study Information: This study plans to learn more about an investigational new drug called lumateperone tosylate (ITI-007) and may help us find new types of treatment for schizophrenia and schizoaffective disorder.
This study is closed
Investigator
Jeffrey Lieberman, MD
Do You Qualify?
Do you have schizophrenia or schizoaffective disorder? Yes No
Are you between the ages of 18-60? Yes No
Have you used another investigational medication in the previous 4 weeks? Yes No
Submit
Cancel
You may be eligible for this study

Place Holder



Cancel
For more information, please contact:
Marlene Carlson, MPH
mc157@columbia.edu
646-774-8436
This website uses cookies as well as similar tools and technologies to understand visitors’ experiences. By continuing to use this website, you consent to Columbia University’s usage of cookies and similar technologies, in accordance with the Columbia University Website Cookie Notice.
I AGREE